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i.org/1patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on
LVH, that is, prevalence and determinants, are inconsistent mainly because of different defini-
tions and heterogeneity of study populations. We determined echocardiographic-based LVH
prevalence and clinical factors independently associated with its development in a prospective
cohort of patients with non-valvular (NV) AF. From the “Atrial Fibrillation Registry for Ankle-
brachial Index Prevalence Assessment: Collaborative Italian Study” (ARAPACIS) population,
1,184 patients withNVAF (meanage 72– 11 years; 56%men)with complete data to define LVH
were selected. ARAPACIS is a multicenter, observational, prospective, longitudinal on-going
study designed to estimate prevalence of peripheral artery disease in patients with NVAF. We
foundahighprevalence ofLVH (52%) in patientswithNVAF.Compared to thosewithoutLVH,
patients with AF with LVH were older and had a higher prevalence of hypertension, diabetes,
and previousmyocardial infarction (MI). A higher prevalence of ankle-brachial index£0.90was
seen in patients with LVH (22 vs 17%, p [ 0.0392). Patients with LVH were at significantly
higher thromboembolic risk,withCHA2DS2-VASc‡2 seen in93%ofLVHand in73%ofpatients
without LVH (p <0.05). Women with LVH had a higher prevalence of concentric hypertrophy
than men (46% vs 29%, p [ 0.0003). Logistic regression analysis demonstrated that female
gender (odds ratio [OR] 2.80, p <0.0001), age (OR 1.03 per year, p <0.001), hypertension (OR
2.30, p <0.001), diabetes (OR 1.62, p [ 0.004), and previous MI (OR 1.96, p [ 0.001) were
independently associated with LVH. In conclusion, patients with NVAF have a high prevalence
of LVH, which is related to female gender, older age, hypertension, and previous MI. These
patients are at high thromboembolic risk and deserve a holistic approach to cardiovascular
prevention.  2015 Elsevier Inc. All rights reserved. (Am J Cardiol 2015;116:877e882)Atrial fibrillation (AF) is the most prevalent supraven-
tricular tachyarrhythmia 1,2 associated with high risk of
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0.1016/j.amjcard.2015.05.060predictor of new onset AF.4e6 One of the hypertension-
related target organ damage is left ventricular hypertro-
phy (LVH).7e10 Data on gender differences in develop-
ment of LVH have been reported in hypertensive patients
with11 or without concomitant heart failure.10 Notwith-
standing different definitions and threshold criteria, LVH
prevalence ranges widely in the general population.10
Nonetheless, LVH is an independent risk factor for ma-
jor cardiovascular events and all cause death.12e15 Also,
left ventricular remodeling has been identified as an in-
dependent risk factor for stroke and mortality in patients
with AF.16 The aim of our study was to determine LVH
prevalence, using well-defined echocardiographic criteria
based on left ventricular mass (LVM) indexed by body
surface area (BSA) in a cohort of patients with non-
valvular (NV) AF. Second, we aimed to identify the
clinical factors independently associated with LVH in our
patients with NVAF. Third, we conducted a gender-
stratified analysis to investigate relevant gender differ-
ences in LVH in patients with NVAF.
Methods
We performed a cross-sectional analysis on the “Atrial
Fibrillation Registry for Ankle-brachial Index Prevalencewww.ajconline.org
Figure 1. Flow diagram of NVAF patient selection.
878 The American Journal of Cardiology (www.ajconline.org)Assessment: Collaborative Italian Study” (ARAPACIS), a
multicenter, observational, prospective on-going study
designed to estimate prevalence of ankle-brachial index
(ABI) 0.90 in patients with NVAF and its influence on
cardiovascular and cerebrovascular events incidence over a
3-year follow-up.17,18
Details on standard study procedures have been previ-
ously reported.18 In addition, a standard transthoracic
echocardiography19 was performed where feasible. Even if
a central analysis of echocardiographic images was not
performed, an experienced cardiologist in echocardiography
performed a blinded evaluation of measurements for con-
sistency and reliability.
Patients were consecutively recruited, both as inpatients
or outpatients, if they were aged 18 years and had NVAF
diagnosis recorded in the preceding 12 months. Enrollment
was performed in 136 facilities belonging to the Italian
Internal Medicine Society network from October 2010 and
continued until 30 October 2012. All patients signed a
written informed consent. The study was conducted in
accordance with the EU Note for Guidance on Good
Clinical Practice CPMP/ECH/135/95 and the Declaration
of Helsinki.
LVM estimation was calculated according to American
Society of Echocardiography (ASE) and European Associa-
tion of Echocardiography (EAE) joint recommendations.19
LVM values have been indexed by BSA, calculated with the
Dubois and Dubois formula (BSA ¼ 0.007184  weight
[Kg]0.425 height [cm]0.725). Thus, we defined the presence of
LVH for an LVM indexed by BSA (LVMI-BSA) >95 g/m2
for women and an LVMI-BSA >115 g/m2 for men.19
The definition of LV remodeling was assessed calcu-
lating the relative wall thickness (RWT). In accordance to
ASE/EAE recommendations,19 RWT 0.42 defined a
concentric remodeling, otherwise an RWT <0.42 defined
an eccentric remodeling. All patients were then catego-
rized into 4 categories of cardiac remodeling: (1) no
remodeling, that is, patients without LVH and with an
RWT <0.42; (2) concentric remodeling, that is, patients
without LVH and with an RWT 0.42; (3) eccentric hy-
pertrophy, that is, patients with LVH and an RWT <0.42;
and (4) concentric hypertrophy, that is, patients with LVH
and an RWT 0.42.
According to ShapiroeWilk normality test, variables
with a normal distribution were tested for differences by theStudent t test and reported as mean  standard deviation.
Variables with nonhomogeneous variances were tested by
the ManneWhitney U test and reported as median and
interquartile range. Categorical variables, expressed as
counts and percentages, were analyzed by a chi-square test.
A gender-stratified analysis was also conducted. Finally, a
multivariate regression analysis was performed to establish
LVH determinants in patients with NVAF. To reduce
interobserver variability, the regression analysis was cor-
rected for enrolling centers. The probability values were 2
sided; a p value <0.05 was considered statistically signifi-
cant. All analyses were carried out with SPSS version 20
(IBM, NY, USA).
Results
Among a total of 2,027 patients enrolled in ARAPACIS,
echocardiographic data were available for 1,184 subjects
(59%). After data revision, 1,087 patients (72  11 years;
56% men) were eligible for analysis (Figure 1). Clinical and
demographic variables in nonincluded patients were similar
to those analyzed (Table 1).
Previous cardiovascular disease was recorded for about 1/4
of patients. Among classic cardiovascular risk factors,
hypertension was the most prevalent (82%). The mean
LVMI-BSA was 112  31 g/m2. Values of LVMI-BSA were
greater in permanent NVAF compared to those with persistent
AF (p ¼ 0.0107) or paroxysmal AF (p ¼ 0.0023). LVMI-
BSA progressively increased with higher CHA2DS2-VASc
risk classes (p <0.0001; Figure 2).
LVH was recorded in 52% of patients. Clinical and
demographic characteristics in the groups are reported in
Table 1. Patients with LVH were older, had a higher prev-
alence of hypertension, diabetes, and previous myocardial
infarction (MI) compared to those without. ABI 0.90 was
prevalent in patients with LVH. CHA2DS2-VASc 2 class
was recorded more frequently in patients with LVH.
Table 2 summarizes echocardiographic characteristics of
the 2 groups. Patients with LVH had poorer ventricular
function compared to those without LVH. In 59% of pa-
tients with LVH, there was a concentric hypertrophy pattern.
Pharmacologic treatments distribution in the 2 groups are
reported in Table 3. Patients with LVH were more likely
treated with oral anticoagulants (OAC) and angiotensin-
converting enzyme inhibitors than those without LVH.
Final forward logistic model showed that female gender
(odds ratio [OR] 2.808, 95% confidence interval [CI] 2.152
to 3.664, p <0.001), age (OR per year 1.035, 95% CI 1.021
to 1.048, p <0.001), hypertension (OR 2.302, 95% CI
1.606 to 3.299, p <0.001), diabetes (OR 1.623, 95% CI
1.169 to 2.253, p ¼ 0.004), and previous MI (OR 1.964,
95% CI 1.328 to 2.903, p ¼ 0.001) were independently
associated with LVH. No influence of enrolling centers was
evident.
LVH was detected in 67% of NVAF women compared to
42% in men. Number of atherosclerotic risk factors was
greater in male patients with LVH compared to those
without (2.04  1.20 vs 1.76  1.02, p ¼ 0.0041). Similar
data were recorded in female patients with LVH compared
to those without (1.92  1.12 vs 1.70  1.10, p ¼ 0.0434).
Concentric hypertrophy was more common in female
Table 1
Clinical and demographic characteristics according to the presence of left ventricular hypertrophy
Variable Excluded Patients
N[ 940
Left Ventricular Hypertrophy P value
Yes vs. No
Yes
N[576
No
N[511
Age (years.), meanSD 749 759 7012 <0.0001*
Age Classes <0.0001†
<65 years 263 (28%) 123 (21%) 191 (37%)
65-74 years 209 (22%) 141 (25%) 142 (28%)
75 years 468 (50%) 312 (54%) 178 (35%)
Women 439 (47%) 353 (56%) 158 (31%) <0.0001†
Body Mass Index (Kg/m2), meanSD 285 285 285 0.4876*
Type of Atrial Fibrillation 0.0866†
Paroxysmal 425 (45%) 233 (41%) 221 (43%)
Persistent 120 (13%) 82 (14%) 90 (18%)
Permanent 395 (42%) 261 (45%) 200 (39%)
Hypertensionz 785 (84%) 515 (89%) 374 (73%) <0.0001†
Diabetes Mellitus 237 (25%) 152 (26%) 77 (15%) <0.0001†
Smoker 138 (15%) 77 (13%) 100 (20%) 0.0057†
Hypercholesterolemiax 353 (38%) 231 (40%) 205 (40%) 0.9964†
Metabolic Syndrome 282 (31%) 164 (30%) 141 (29%) 0.6767†
Previous Transient Ischemic Attack/Stroke 116 (12%) 67 (12%) 52 (10%) 0.4429†
Previous Myocardial Infarction 159 (17%) 105 (18%) 49 (9.6%) <0.0001†
Previous Peripheral Artery Disease 13 (1.4%) 9 (1.4%) 10 (1.9%) 0.5624†
Heart Failure 189 (20%) 102 (18%) 87 (17%) 0.7668†
Ankle-Brachial Index 0.90{ 212 (23%) 128 (22%) 88 (17%) 0.0391†
CHA2DS2-VASc, median [IQR] 3 [2-4] 4 [3-5] 2 [1-4] <0.0001
k
CHA2DS2-VASc Classes <0.0001
†
Score 0 25 (2.7%) 8 (1.4%) 46 (9.0%)
Score 1 108 (11.5%) 35 (6.1%) 94 (18.4%)
Score2 807 (85.8%) 533 (92.5%) 371 (72.6%)
IQR ¼ Interquartile Range; SD ¼ Standard Deviation.
* Student t test.
† Chi-square test.
z Blood Pressure>140/90 mm Hg or treated with anti-hypertensive drugs.
x Total Cholesterol 240 mg/dl or treated with lipid lowering drugs.
{ Data referred to 1,084 patients.
kMann Whitney U test.
Figure 2. LVMI-BSA values distribution according to CHA2DS2-VASc
score.
Arrhythmias and Conduction Disturbances/LVH in Atrial Fibrillation 879patients (F ¼ 46% vs M ¼ 29%, p ¼ 0.0003). Women with
LVH, compared with men, were less treated with OAC
(65% vs 69%, p ¼ 0.0318).Discussion
The present analysis of a selected cohort from the
ARAPACIS study provides, for the first time, data on the
high prevalence of LVH, defined as LVM indexed by BSA.
Second, we identified female gender, age, hypertension,
diabetes, and previous MI as clinical factors associated with
the presence of LVH in patients with NVAF. Third, we
observed that concentric hypertrophy was the most common
remodeling pattern in female patients with NVAF.
These findings could contribute to a better understanding
of ventricular remodeling in patients with NVAF. In fact,
previous clinical studies reported a huge range (from 23% to
68%) of LVH prevalence in AF,15,16 probably because of
heterogeneity of patients enrolled or to different LVH
evaluations.15,16 Using a standard recommended method for
LVH definition, we have now provided more reliable data
on LVH prevalence in patients with NVAF. Second, taking
in account that LVMI-BSA seems to be one of the most
reliable method to determine the cardiovascular risk asso-
ciated with left ventricular remodeling,20 our work could
represent a premise for evaluating clinical usefulness of
LVH detection in cardiovascular risk assessment also in
Table 2
Echocardiographic characteristics according to the presence of left ventricular hypertrophy
Variable Left Ventricular Hypertrophy P
Yes
N[576
No
N[511
Left Ventricular Ejection Fraction (%), meanSD 5410 578 <0.0001*
Left Ventricular Ejection Fraction <50% 133 (23%) 62 (12%) <0.0001†
Left Ventricular Mass Indexed by Body Surface Area (g/m2), meanSD 13227 8915 <0.0001*
Relative Wall Thickness (>0.42) 338 (59%) 215 (42%) <0.0001†
Left Ventricular Internal End-Diastolic Dimension (mm), meanSD 536 485 <0.0001*
Interventricular Septum Thickness (mm), meanSD 122 102 <0.0001*
Posterior Wall Thickness (mm), meanSD 112 91 <0.0001*
Left Atrial Diameter (mm), meanSDz 458 449 0.2488*
Cardiac Remodeling <0.0001†
None Remodeling 0 (0) 296 (58%)
Concentric Remodeling 0 (0) 215 (42%)
Eccentric Hypertrophy 238 (41%) 0 (0)
Concentric Hypertrophy 338 (59%) 0 (0)
SD ¼ Standard Deviation.
* Student t test.
† Chi-square test.
z Data referred to 912 patients.
Table 3
Pharmacologic treatments distribution according to the presence of left
ventricular hypertrophy
Variable Left Ventricular Hypertrophy P*
Yes
N[576
No
N[511
Anti-Thrombotic 0.0134
None 48 (8.3%) 62 (12%)
Oral Anticoagulant 381 (66%) 309 (61%)
Antiplatelets 117 (20%) 125 (25%)
Oral AnticoagulantþAntiplatelets 30 (5.1%) 15 (2.9%)
Statins 218 (38%) 189 (37%) 0.7697
Beta-Blockers 260 (45%) 213 (42%) 0.2513
Angiotensin-Converting-Enzyme
Inhibitors
222 (39%) 155 (30%) 0.0045
Angiotensin II Receptor Blockers 212 (37%) 169 (33%) 0.1979
Calcium Channel Blockers 165 (29%) 127 (25%) 0.1591
Nitrates 83 (14%) 38 (7.4%) 0.0002
Antiarrhythmics 159 (28%) 156 (31%) 0.2888
Digoxin 117 (20%) 64 (13%) 0.0005
Diuretics† 293 (60%) 193 (45%) <0.0001
Oral Hypoglycemic Agents 92 (16%) 52 (10%) 0.0049
Subcutaneous Insulin 44 (7.6%) 11 (2.1%) <0.0001
* Chi-square test.
† Data referred to 859 patients.
880 The American Journal of Cardiology (www.ajconline.org)patients with NVAF. Indeed, higher prevalence of ABI
0.90 could suggest an association between atherosclerosis
and LVH,21,22 which requires further investigations. More-
over, the recognition of LVH may play a pivotal role to
correctly stratify cerebrovascular risk of patients with
NVAF as reported in hypertensive patients.23,24 In fact,
previous data demonstrated that increased LVM, and
abnormal RWT, are associated with increased risk of stroke
in hypertensive patients, even higher in patients with a
concentric pattern.24A post hoc analysis from the Atrial Fibrillation Follow-
up Investigation of Rhythm Management (AFFIRM)
trial16 reported that LVH assessed by LVM was an inde-
pendent predictor of both all-cause mortality and stroke in
patients with AF.16 Further evaluations of follow-up data of
ARAPACIS study will provide a relevant evidence to clarify
this poorly explored issue.
Although patients with LVH are at greater thromboem-
bolic risk, we found suboptimal OAC use, as previously
reported for the overall ARAPACIS study population.17
Moreover, female patients with LVH seem to be signifi-
cantly less treated with OAC. Considering the higher stroke
risk in women with LVH compared to men with or without
LVH,25,26 the underuse of OAC could contribute to the
higher stroke risk of female patients. The standard evalua-
tion of LVH presence in patients with NVAF could be
useful to better define thromboembolic risk, independently
by other thromboembolism risk factors. When available,
prospective data coming from ARAPACIS study might
clarify this aspect.
Our data suggest that different LVH development among
sex might be relevant in stratifying thromboembolic risks of
patients with NVAF. The prevalence of concentric hyper-
trophy in our female patients with NVAF was significantly
higher compared with men. Indeed, experimental data sug-
gest that cardiac hypertrophy development in response to a
pathologic stimulus may be blunted in women compared
with men,27 yet the relative mortality risk, when hypertro-
phy does occur, is greater in women and is more commonly
concentric.28,29 As stated previously, concentric hypertro-
phy in hypertensive patients carries the greatest stroke
risk.24 Furthermore, gender differences in LVH distribution
and worse cardiac remodeling in patients with NVAF may
partly explain why female gender confers additional risk of
thromboembolic stroke. Accordingly, the presence of LVH,
as defined by electrocardiography, confers a greater stroke
risk of in patients with LVH AF.15
Arrhythmias and Conduction Disturbances/LVH in Atrial Fibrillation 881As with any observational analysis, residual unmeasured
confounders may exist and impact the validity of our results.
Given the cross-sectional nature of the study, data presented
cannot establish a pathophysiological link between NVAF
and LVH but provide hypothesis-generating associations.
Given that hypertension was highly prevalent in patients
with NVAF and because hypertension represents a funda-
mental risk factor for the developing of LVH, we cannot
establish whether LVH was evident before the development
of NVAF. Finally, the present analysis is based on the
assumption that walls thickness and geometry are homog-
enous. This assumption could bias the evaluation of LVH
prevalence, even if reduced by the use of 3 different mea-
surements to assess LVM.
To summarize, patients with NVAF have a high preva-
lence of LVH, which is related to female gender, older age,
hypertension, and previous MI. Ongoing prospective data
from the ARAPACIS study will clarify the potential
predictive role of LVH in patients with NVAF.Disclosures
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